We’re one of the first firms to deliver coverage of foreign growth companies tailored specifically to U.S. investors.
Our research reports are available to our clients. If you are an existing client and already have a username and password, please login. If you are an existing client and want to register for access to the site, please use the registration form below.
If you are a potential client and are interested in finding out how Chardan can help you, please contact Shai Gerson at 646-465-9008.
|Lowering To Neutral; Raising PT To $296||Log In or Register|
|October 17, 2012||NPSP VVUS||Healthcare||Andrew Fein||Log In or Register|
|November 19, 2012||Neostem Inc.||3Q Update: Believe Data, Acquisitions Could Drive Investor Interest in 2013||Healthcare||NBS||Buy||Andrew Fein||Log In or Register|
|December 11, 2012||Our Thoughts From ASH||Healthcare||Andrew Fein||Log In or Register|
|February 13, 2013||CEL-SCI Corporation||Initiating Coverage with BUY Rating and $0.90 PT||Healthcare||CVM||Buy||Andrew Fein||Log In or Register|
|March 11, 2013||Neostem Inc.||DSMB Grants All Clear: PreSERVE Continues as Planned||Healthcare||NBS||Buy||Andrew Fein||Log In or Register|
|March 20, 2013||Amarin Corporation||Initiating with Neutral Rating and $8.50 PT: Not All Squeaks Have Been Oiled||Healthcare||AMRN||Neutral||Andrew Fein||Log In or Register|
|April 10, 2013||Vertex Pharmaceuticals||Initiating with BUY and $80 PT: A Paradoxical Arbitrage||Healthcare||VRTX||Buy||Andrew Fein||Log In or Register|
|April 19, 2013||Vertex Pharmaceuticals||Breathing a Sigh of Relief (or Just as We Had Expected) – Raising PT to $105||Healthcare||VRTX||Buy||Andrew Fein||Log In or Register|
|April 23, 2013||Amarin Corporation||sNDA for ANCHOR Accepted: A Big So What||Healthcare||AMRN||Neutral||Andrew Fein||Log In or Register|